637 related articles for article (PubMed ID: 25490451)
1. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Christensen CL; Kwiatkowski N; Abraham BJ; Carretero J; Al-Shahrour F; Zhang T; Chipumuro E; Herter-Sprie GS; Akbay EA; Altabef A; Zhang J; Shimamura T; Capelletti M; Reibel JB; Cavanaugh JD; Gao P; Liu Y; Michaelsen SR; Poulsen HS; Aref AR; Barbie DA; Bradner JE; George RE; Gray NS; Young RA; Wong KK
Cancer Cell; 2014 Dec; 26(6):909-922. PubMed ID: 25490451
[TBL] [Abstract][Full Text] [Related]
2. Treating transcriptional addiction in small cell lung cancer.
Augert A; MacPherson D
Cancer Cell; 2014 Dec; 26(6):783-784. PubMed ID: 25490443
[TBL] [Abstract][Full Text] [Related]
3. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
4. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
5. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
[TBL] [Abstract][Full Text] [Related]
6. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
[TBL] [Abstract][Full Text] [Related]
7. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
Kwiatkowski N; Zhang T; Rahl PB; Abraham BJ; Reddy J; Ficarro SB; Dastur A; Amzallag A; Ramaswamy S; Tesar B; Jenkins CE; Hannett NM; McMillin D; Sanda T; Sim T; Kim ND; Look T; Mitsiades CS; Weng AP; Brown JR; Benes CH; Marto JA; Young RA; Gray NS
Nature; 2014 Jul; 511(7511):616-20. PubMed ID: 25043025
[TBL] [Abstract][Full Text] [Related]
8. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
[TBL] [Abstract][Full Text] [Related]
9. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
Zhang Z; Peng H; Wang X; Yin X; Ma P; Jing Y; Cai MC; Liu J; Zhang M; Zhang S; Shi K; Gao WQ; Di W; Zhuang G
Mol Cancer Ther; 2017 Sep; 16(9):1739-1750. PubMed ID: 28572168
[TBL] [Abstract][Full Text] [Related]
11. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.
Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC
Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525
[TBL] [Abstract][Full Text] [Related]
12. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
13. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
14. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
16. CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II.
Sun Y; Zhang Y; Schultz CW; Pommier Y; Thomas A
Mol Cancer Ther; 2022 Sep; 21(9):1430-1438. PubMed ID: 35830858
[TBL] [Abstract][Full Text] [Related]
17. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
18. Effective Killing of Cancer Cells Through ROS-Mediated Mechanisms by AMRI-59 Targeting Peroxiredoxin I.
Yang YJ; Baek JY; Goo J; Shin Y; Park JK; Jang JY; Wang SB; Jeong W; Lee HJ; Um HD; Lee SK; Choi Y; Rhee SG; Chang TS
Antioxid Redox Signal; 2016 Mar; 24(8):453-69. PubMed ID: 26528922
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
